Other Pain Disorders – Pipeline Review, H2 2012

Other Pain Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Pain Disorders - Pipeline Review, H2 2012', provides an overview of the Other Pain Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Pain Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Pain Disorders. 'Other Pain Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Pain Disorders.
- A review of the Other Pain Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Pain Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Pain Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Pain Disorders pipeline depth and focus of Other Pain Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Other Pain Disorders Overview 6
Therapeutics Development 7
Therapeutics Development 7
An Overview of Pipeline Products for Other Pain Disorders 7
Other Pain Disorders Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Other Pain Disorders Therapeutics – Products under Investigation by Universities/Institutes 13
Other Pain Disorders – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
Acetylsalicylic acid + Sodium bicarbonate + Citric acid - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Aspirin + Sodium Bicarbonate + Citric Acid - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Triamcinolone + Lidocaine - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Doxepin Hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Celecoxib - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Tylenol + Codeine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Imipramine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Fentanyl - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Morphine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Pregabalin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Pregabalin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Other Pain Disorders Therapeutics – Discontinued Products 33
Other Pain Disorders Therapeutics - Dormant Products 34
Other Pain Disorders – Product Development Milestones 35
Featured News & Press Releases 35
Oct 20, 2010: Quark Initiates Phase I Study Of QPI-1007 For Treatment Of Ischemic Optic Neuropathy 35
Aug 09, 2010: Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain 35
Mar 30, 2010: NeuroVive Completes Clinical Trial With Cremophor-Free Intravenous Cyclosporine Formula NeuroSTAT 36
Mar 18, 2010: Spinal Restoration Initiates Patient Enrollment For Phase III Study Of Company's Biostat System 37
Dec 15, 2009: Spinal Restoration Receives FDA SPA Concurrence Letter For its Phase III Biostat System Study 38
Feb 07, 2003: Watson Pharmaceuticals Completes Purchase of Fiorinal and Fioricet Pain Product Lines 38
Jan 22, 2003: Watson to Acquire Line of Pain Products including Fiorinal 38
Sep 05, 1995: Watson Pharmaceuticals Announces FDA Approval For Fiorinal With Codeine Capsule 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Other Pain Disorders, H2 2012 7
Products under Development for Other Pain Disorders – Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Assessment by Monotherapy Products, H2 2012 14
Assessment by Combination Products, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 19
Other Pain Disorders Therapeutics – Discontinued Products 33
Other Pain Disorders Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Other Pain Disorders, H2 2012 7
Products under Development for Other Pain Disorders – Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 14
Assessment by Combination Products, H2 2012 15
Assessment by Route of Administration, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Molecule Type, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 19